



FDA grants Orphan Drug Designation for the use of teicoplanin in *Staphylococcus aureus* infections in cystic fibrosis patients

RP announcement

Milan, July 10th 2018 Neupharma and Rare Partners announce that they received from FDA on May 24th the granting of Orphan Drug Designation for the use of teicoplanin in the treatment of *Staphylococcus aureus* infections in cystic fibrosis patients.

The designation obtained in USA follows an analogue decision taken by the European agency EMA on August 23rd 2017.

The Italian biotech Neupharma and the non profit company Rare Partners, both active in the field of rare diseases, have developed an innovative inhalable formulation of teicoplanin that could start the first clinical trial before the end of 2018.

Fabio Borella, President and co- founder of Neupharma, said: *“Pulmonary infections caused by resistant germs and in particular by Methicillin resistant Staphylococcus aureus (MRSA) are a relevant emergency in patients affected by cystic fibrosis. The granting of orphan drug designation both in Europe and USA in this rare therapeutic indication confirms the great interest for an inhaled formulation of teicoplanin. Neupharma is leader in Italy in the field of inhalatory treatments, thanks to its partnership with major international players. This project will allow Neupharma to have its own product in the two major markets, EU and USA”.*

Marco Prosdociami, Managing Director of Rare Partners, said: *"We are extremely satisfied with the collaboration established in recent years with Neupharma, a company that is a reference point in our country for doctors and at the forefront in the treatment of respiratory infections, cystic fibrosis in particular. The two designations obtained for inhaled teicoplanin in Europe and USA represent an important milestone that confirms the potential value of this innovative project".*



About Rare Partners

Rare Partners is a non profit biopharmaceutical company devoted to the development of new therapies and diagnostics in the field of rare diseases. The company was founded in Milan on March 2010 and registered in Italy as “Impresa Sociale”. The basic idea of Rare Partners is to match non profit financial resources (public and private) with industrial drug development expertise, provided by the company’s organization together with a strong network of consultants. Rare Partners presently has development projects in the fields of thalassemia, cystic fibrosis and Usher syndrome.

www.rarepartners.org

About Neupharma

Neupharma is a young and modern company focused on innovation aiming at rare diseases, particularly cystic fibrosis. Neupharma is market leader in Italy for the inhaled treatment of chronic *Pseudomonas aeruginosa* lung infections. Neupharma distributes in Italy the most advanced medical devices for the inhalation therapy in cooperation with the world leader Pari GmbH.

www.neupharma.it

For further information, please contact:

Marco Prosdocimi, Managing Director, Rare Partners Srl

m.prosdocimi@rarepartners.org